Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

This policy covers the use of progenitor (stem) cell therapies and related cell/tissue‑engineered products to repair or regenerate myocardium damaged by acute or chronic cardiac ischemia, including acute myocardial infarction, refractory/intractable angina, and ischemic heart disease. These interventions (e.g., MyoCell, Ixmyelocel‑T, MultiStem, CardiAMP) are considered experimental/investigational and not FDA‑approved, with coverage limited pending robust phase‑3 randomized evidence (preferably ≥100 patients per arm) and systematic reviews; infusion of growth‑factor mobilization is also investigational.

"Treatment of damaged myocardium resulting from acute cardiac ischemia"

Sign up to see full coverage criteria, indications, and limitations.